目的 研究孟鲁司特钠咀嚼片体外溶出及渗透过程,并建立体内外相关性模型对仿制制剂的生物等效性进行预测。方法 采用Macro Flux型药物溶出度与渗透速率测试系统,以饱腹小肠模拟液(pH 5.0)为介质,分别比较参比制剂和受试制剂的溶出及渗透行为,通过关键质量参数考察药物的释放与吸收过程,预测受试制剂的生物利用度,进而预测制剂间是否生物等效。结果 在饱腹小肠模拟液中,孟鲁司特钠咀嚼片受试制剂与参比制剂的溶出行为和渗透速率基本一致,ρmax和AUC0-t无显著性差异,生物利用度约为参比制剂的97%。结论 初步预测孟鲁司特钠咀嚼片受试制剂与参比制剂在体内生物等效。
Abstract
OBJECTIVE To study the in vitro dissolution and permeation process of montelukast sodium chewable tablets, and establish the in vivo-in vitro correlation models to predict the bioequivalence of the generic preparations. METHODS The Macro Flux drug dissolution absorption test system was used, and the satiety intestinal simulated liquid (pH 5.0) was used as the medium to compare the penetration of the reference preparation and test preparation. The rate, release and absorption process of the drug were examined by the quality parameters, and the bioavailability of the test preparation was predicted, thereby predicting whether the preparation was bioequivalent. RESULTS In the satiety small intestine simulating solution, the permeation rate, ρmax and AUC0-t of the test preparation and the reference preparation were basically the same. The bioavailability was approximately 97% of the reference formulation. CONCLUSION It is preliminarily predicted that the test preparation of montelukast sodium chewable tablets is bioequivalent with the reference preparation.
关键词
孟鲁司特钠咀嚼片 /
渗透速率 /
生物等效性 /
生物利用度
{{custom_keyword}} /
Key words
montelukast sodium chewable tablet /
permeation rate /
bioequivalence /
bioavailability
{{custom_keyword}} /
中图分类号：
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]JONES T R,LABELLE M, BELLEY M, et al. Pharmacology of montelukast sodium (SingulairTM), a potent and selective leukotriene D4 receptor antagonist [J]. Can J Physiol Pharmacol,1995,73 (2):191-201.
[2]THIBERT R,MACH H,CLAS S D, et al. Characterization of the self-association properties of a leukotriene D4 receptor antagonist, MK-0476 [J]. Int J Pharm,1996,134 (1-2):59-70.
[3]SONG X F, ZHAO C, HU Z Y. Study on determination methods of related substances in montelukast sodium chewable tablets [J]. Chin J New Drug (中国新药杂志),2016,25(6):681-686.
[4]AVDEEF A. The rise of PAMPA [J]. Expert Opin, 2005, 1(2):325-342.
[5]HIDALGO I J. Assessing the absorption of new pharmaceuticals [J]. Curr Top Med Chem,2001,1(5):385-401.
[6]LENNERNAS H. Intestinal permeability and its relevance forabsorption and elimination [J]. Xenobiotica, 2007,37(10-11):1015-1051.
[7]KANSY M, AVDEEF A, FISCHER H. Advances in screening for membrane permeability:high-resolution PAMPA for medicinal chemists [J]. Drug Discov Today Technol,2004,1(4):349-355.
[8]ENIKÅB, ATTILA B, KATALIN B, et al. In vitro dissolution-permeation evaluation of an electrospun cyclodextrin-based formulation of aripiprazole using μFluxTM [J]. Int J Pharm,2015,491(1-2):180-189.
[9]ZHAO H Y, LIU G Z, WANG S, et al. Preliminary prediction of bioequivalence of leflunomide tablets based on analysis of solublility and permeability [J]. Chin Pharm J (中国药学杂志),2018,53(13):1117-1122.
[10]ALEX A, STEFANIE B, LI D I, et al. PAMPA-Critical factors for better predictions of absorption [J]. J Pharm Sci,2007, 96 (11):2893-2909.
[11]AVDEEF A, ARTURSSON P, NEUHOFF S, et al. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method [J]. Eur J Pharm, 2005, 24 (4):333-349.
[12]Ch.P(2015)Vol Ⅱ(中国药典2015年版.二部)[S]. 2015:121.
[13]LIU H, SABUS C, GUY T, et al. In vitro, permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection[J]. Pharm Res,2003,20(11):1820-1826.
[14]ENIKO B. The effect of formulation additives on in vitro dissolution-absorption profile and in vivo bioavailability of telmisartan from brand and generic formulations[J]. Eur J Pharm, 2018, 114(3):310-317.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
“重大新药创制”国家科技重大专项项目资助(2017ZX09101001)
{{custom_fund}}
PDF(1384 KB)
